Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Radiation for Early Stage dMMR Endometrial Cancer
NCT04214067Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of pembrolizumab in endometrial cancer (EC), sponsored by National Cancer Institute. Started Apr 2020; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04214067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214067.